Recent News

• 05.20.2025 - Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
• 05.14.2025 - FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
• 05.08.2025 - Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
• 04.29.2025 - Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
• 04.16.2025 - BDD’s OralogiK™ Technology Powers Advancement of A Once-Daily Anxiety Treatment
• 04.09.2025 - Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)
• 04.03.2025 - Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
• 03.26.2025 - Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Recent Filings

• 05.13.2025 - 8-K Current report
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - 8-K Current report
• 05.08.2025 - EX-99.1 EX-99.1
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.15.2025 - PRE 14A Other preliminary proxy statements
• 04.09.2025 - EX-99.1 EX-99.1
• 04.09.2025 - 8-K Current report